Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (EGFR [ErbB1]) and of HER2 [ErbB2], which inhibits ErbB-driven tumor cell growth. Here, ERBB2 is linked to neoplasm.